Comparison between photodynamic therapy with ranibizumab and fixed dosing aflibercept for polypoidal choroidal vasculopathy
Not Applicable
- Conditions
- Polypoidal choroidal vasculopathy
- Registration Number
- JPRN-UMIN000029148
- Lead Sponsor
- The Japanese Red Cross Nagasaki Genbaku Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)Concurrent ocular diseases affecting visual acuity 2)Previous treatment for PCV 3)History of intraocular surgery other than phacoemulsification
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of best-corrected visual acuity 3, 12 and 24 months after treatment
- Secondary Outcome Measures
Name Time Method